Senti Biosciences (NASDAQ:SNTI – Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.67) earnings per share (EPS) for the quarter, Zacks reports.
Senti Biosciences Price Performance
SNTI traded down $0.11 during trading on Thursday, reaching $3.51. 16,781 shares of the stock were exchanged, compared to its average volume of 781,284. The business’s 50 day moving average price is $3.95 and its two-hundred day moving average price is $3.44. The company has a market capitalization of $16.95 million, a price-to-earnings ratio of -0.23 and a beta of 2.52. Senti Biosciences has a 1 year low of $1.52 and a 1 year high of $16.94.
Wall Street Analyst Weigh In
Separately, Chardan Capital reaffirmed a “buy” rating and set a $10.00 price objective on shares of Senti Biosciences in a report on Monday, December 2nd.
About Senti Biosciences
Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.
Featured Articles
- Five stocks we like better than Senti Biosciences
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Everything About Amazon Stock Signals a Buy—Time to Load Up?
- How to Invest in Insurance Companies: A Guide
- 5 Reasons Five Below’s Stock Price Is Heading Higher This Year
- How to Use the MarketBeat Dividend Calculator
- Broadcom: Why the Chip Stock Remains a Top Long-Term AI Play
Receive News & Ratings for Senti Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senti Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
